Dilution of per-share value from the exercise of stock options
First written in FY2021. 12 of 16 entries say "Materialised", first in FY2022-Q2. Latest entry: FY2026.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2026MaterialisedAnnual report
「9 August 2025–30 March 2026 76,200 41,840,875 13,435 68,917 13,435 6,265,898」
During the fiscal year, 76,200 shares were issued through the exercise of stock acquisition rights, and stated capital and the capital reserve each increased by ¥13.435 million. - FY2026-H1MitigatedAnnual report
「During the interim accounting period, the following stock acquisition rights expired.」
The 10th, 13th, 5th, 6th and 7th Series Stock Acquisition Rights expired, eliminating the potential dilution factor associated with a total of 690,400 shares. - FY2025MitigatedAnnual report
「As of the end of May 2025, the number of potential shares attributable to these stock acquisition rights was 1,306,500, equivalent to 3.1% of the total number of shares issued, 41,761,392.」
The number of potential shares and their ratio to total shares issued declined from the previously stated 1,996,900 shares and 4.8% to 1,306,500 shares and 3.1%. - FY2025-H1MitigatedAnnual report
「During the interim accounting period, the following stock acquisition rights expired.」
During the interim accounting period, the 12th, 10th and 13th Series Stock Acquisition Rights expired, eliminating the potential dilution factor associated with a total of 407,000 shares. - FY2024MaterialisedAnnual report
「As of the end of May 2024, the number of potential shares attributable to these stock acquisition rights was 1,996,900, equivalent to 4.8% of the total number of shares issued, 41,751,303.」
Share issuance through the exercise of stock acquisition rights continued during the fiscal year. The number of potential shares was stated as 1,996,900, representing 4.8% of the total number of shares issued. - FY2024-Q3MaterialisedAnnual report
「1 October 2023–31 December 2023 99,400 41,712,203 18,195 45,015 18,195 6,241,996 (Note) The increase resulted from the exercise of stock acquisition rights.」
During the third quarter, 99,400 shares were issued through the exercise of stock acquisition rights, and stated capital and the capital reserve each increased by ¥18.195 million. The dilution factor continues to materialise. - FY2024-Q2MaterialisedAnnual report
「The issuance of new shares upon the exercise of stock acquisition rights increased stated capital and capital surplus by ¥909.123 million each.」
New shares were issued through the exercise of stock acquisition rights, and stated capital and capital surplus each increased by ¥909.123 million. The dilution factor also materialised during the cumulative second-quarter period. - FY2024-Q1MaterialisedAnnual report
「Number of bonds with stock acquisition rights subject to adjustment of the exercise price, etc., exercised during the quarter: 29,700; number of shares delivered in connection with the exercise of rights during the quarter: 2,970,000 shares; funding raised through the exercise of rights during the quarter: ¥1,771.07 million」
Through the exercise of the 16th Series Stock Acquisition Rights, 2,970,000 shares were delivered and ¥1,771.07 million was raised. The dilution factor from the exercise of stock acquisition rights has materialised. - FY2023MaterialisedAnnual report
「1 April 2022–31 March 2023 (Note) 15 2,770,600 38,525,780 706,050 3,270,235 706,050 5,754,007」
During the fiscal year, 2,770,600 shares were issued through the exercise of stock acquisition rights, and stated capital and the capital reserve each increased by ¥706.05 million. As of the filing date, the number of potential shares was stated as 2,235,900, or 5.4% of the total number of shares issued. - FY2023-Q3MaterialisedAnnual report
「Number of bonds with stock acquisition rights subject to adjustment of the exercise price, etc., exercised during the quarter: 3,086 Number of shares delivered in connection with the exercise of rights during the quarter: 308,600 shares Funding raised through the exercise of rights during the quarter: ¥207.282 million」
During the quarter, 308,600 shares were issued through the exercise of the 14th Series Stock Acquisition Rights, raising ¥207.282 million. The cumulative number of shares delivered reached 988,800, and cumulative funding reached ¥668.185 million. - FY2023-Q2MaterialisedAnnual report
「The exercise of stock acquisition rights increased stated capital and capital surplus by ¥26.397 million each.」
During the second quarter, 108,300 shares were issued through the exercise of stock acquisition rights, and stated capital and the capital reserve each increased by ¥19.152 million. The dilution factor continues to materialise. - FY2023-Q1MaterialisedAnnual report
「1 April 2022–30 June 2022 41,400 35,796,580 7,245 2,571,430 7,245 5,055,201 (Note) 1. Stock acquisition rights The increase resulted from the exercise of stock acquisition rights.」
During the first quarter, 41,400 shares were issued through the exercise of stock acquisition rights, and stated capital and the capital reserve each increased by ¥7.245 million. Additional exercises were also reported after the filing. - FY2022MaterialisedAnnual report
「Number of bonds with stock acquisition rights subject to adjustment of the exercise price, etc., exercised during the period: 6,802; number of shares delivered in connection with the exercise of rights during the period: 680,200 shares」
During the fiscal year, 680,200 shares were delivered through the exercise of the 14th Series Stock Acquisition Rights, indicating that the dilution factor has materialised. - FY2022-Q3MaterialisedAnnual report
「Number of shares delivered in connection with the exercise of rights during the quarter: 28,800 shares」
During the quarter, 28,800 shares were delivered through the exercise of the 14th Series Stock Acquisition Rights, generating ¥19 million in funding. The dilution factors of increases in shares issued, stated capital and the capital reserve continue to materialise. - FY2022-Q2MaterialisedAnnual report
「1 July 2021–30 September 2021 Change in total shares issued: 246,200 shares; change in stated capital: ¥44.885 million. (Note) 1. This increase resulted from the exercise of stock acquisition rights.」
During the quarter, 246,200 shares were issued through the exercise of stock acquisition rights, and stated capital and the capital reserve each increased by ¥44.885 million, indicating that the dilution factor has materialised. - FY2021First statedAnnual report
「As of the filing date, the number of potential shares attributable to stock acquisition rights was 3,056,000, equivalent to 8.8% of the total number of shares issued.」
The potential dilution of existing shareholders’ share value and voting rights from the exercise of stock acquisition rights is stated as 3,056,000 potential shares, or 8.8%.